Sugi Predict

Sugi Predict / Compounds / SCHEMBL304157

SCHEMBL304157

SCHEMBL304157

CC(C)(C)OC(=O)OCI

nearest known ligand 0.36

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 2/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ ELANE P08246 1/20 0.35
▸ DGAT1 O75907 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ AKT1 P31749 1/20 0.30
▸ GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597430 0.82 HDAC6 (0.37) HDAC6HDAC1HDAC2ELANEDGAT1
SCHEMBL12519845 0.79 HDAC6 (0.38) HDAC6HDAC1HDAC2ELANEDGAT1
SCHEMBL8861379 0.78 HDAC6 (0.35) HDAC6HDAC1HDAC2ELANEDGAT1
SCHEMBL6754575 0.77 HDAC6 (0.37) HDAC6HDAC1HDAC2ELANEDGAT1
SCHEMBL187396 0.77 ALDH1A1 (0.60) HDAC6HDAC1HDAC2ELANEDGAT1
SCHEMBL17215147 0.76 HDAC6 (0.34) HDAC6HDAC1HDAC2ELANEDGAT1
SCHEMBL6078616 0.76 HDAC6 (0.34) HDAC6HDAC1HDAC2ELANEDGAT1
SCHEMBL4393654 0.75 HDAC6 (0.40) HDAC6HDAC1HDAC2ELANEDGAT1
SCHEMBL5965000 0.75 HDAC6 (0.36) HDAC6HDAC1HDAC2ELANEDGAT1
SCHEMBL5964998 0.75 HDAC6 (0.36) HDAC6HDAC1HDAC2ELANEDGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115175-A1 NICORANDIL DERIVATIVES UNICYCIVE THERAPEUTICS INC (US) 2026-04-30 — — US disclosed
EP-3937938-B1 NICORANDIL DERIVATIVES UNICYCIVE THERAPEUTICS INC (US) 2026-01-28 — — EP disclosed
US-12396989-B2 Nicorandil derivatives UNICYCIVE THERAPEUTICS, INC. (US) 2025-08-26 — — US disclosed
US-12377082-B2 Nicorandil derivatives Unicycive Therapeutics Inc. (US) 2025-08-05 — — US disclosed
US-20240390348-A1 NICORANDIL DERIVATIVES Unicycive Therapeutics Inc. 2024-11-28 — — US disclosed
US-12036211-B2 Nicorandil derivatives Unicycive Therapeutics Inc. (US) 2024-07-16 — — US disclosed
US-12036211-B2 Nicorandil derivatives Unicycive Therapeutics Inc. (US) 2024-07-16 — — US disclosed
US-20230310398-A1 NICORANDIL DERIVATIVES Unicycive Therapeutics Inc. 2023-10-05 — — US disclosed
US-20230310398-A1 NICORANDIL DERIVATIVES Unicycive Therapeutics Inc. 2023-10-05 — — US disclosed
CN-109608436-B Substituted methyl formyl reagents and methods of using same to improve physicochemical and/or pharmacokinetic properties of compounds 斯法尔制药私人有限公司 2022-10-11 — — CN disclosed
US-20070149462-A1 Nucleotide and oligonucleotide prodrugs SPRING BANK PHARMACEUTICALS, INC. 2007-06-28 — — US disclosed
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2007-01-04 — — US disclosed
US-20020147333-A1 2-(pyrazol-3-yl)carbapenem derivatives SMITHKLINE BEECHAM P.L.C. 2002-10-10 — — US disclosed
EP-0915843-A1 AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSES SMITHKLINE BEECHAM PLC (GB) 1999-05-19 — — EP disclosed
US-5869477-A ANTIBACTERIAL ACTIVITIES AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA EXCLUDING PSEUDOMONAS AERUGINOSA KOREA RESEARCH INSTITUTE OF CHEMISTRY TECHNOLOGY (KR) 1999-02-09 — — US disclosed
EP-0869943-A1 MONOCYCLIC BETA-LACTAME DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1998-10-14 — — EP disclosed
CN-1167486-A 2- (pyrazol-3-yl) carbapenem derivatives SMITHKLINE BEECHAM PLC (GB) 1997-12-10 — — CN disclosed
WO-1997041098-A1 AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1997-11-06 — — WO disclosed
WO-1997021675-A1 MONOCYCLIC BETA-LACTAME DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1997-06-19 — — WO disclosed
US-4426391-A [(Alkoxycarbonyl)oxy]alkyl esters of methyldopa MERCK & CO., INC. (US) 1984-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240390348-A1 NICORANDIL DERIVATIVES NAPRT, NQO1, NME4 HDAC6 388/4885HDAC1 959/4885HDAC2 971/4885
US-12377082-B2 Nicorandil derivatives NAPRT, NQO1, NME4 HDAC6 388/4885HDAC1 959/4885HDAC2 971/4885
US-20260115175-A1 NICORANDIL DERIVATIVES XDH, MT-ND4L, NNT HDAC6 1705/4885HDAC1 2631/4885HDAC2 3250/4885
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MTAP, BLVRB, BPGM HDAC6 380/4885HDAC1 499/4885HDAC2 393/4885
US-20070149462-A1 Nucleotide and oligonucleotide prodrugs TYMP, PNP, DUT HDAC6 2953/4885HDAC1 2609/4885HDAC2 3314/4885
US-20230310398-A1 NICORANDIL DERIVATIVES NAPRT, NQO1, NME4 HDAC6 388/4885HDAC1 959/4885HDAC2 971/4885
US-12396989-B2 Nicorandil derivatives NAPRT, NQO1, NME4 HDAC6 388/4885HDAC1 959/4885HDAC2 971/4885
US-12036211-B2 Nicorandil derivatives NAPRT, NQO1, NME4 HDAC6 388/4885HDAC1 959/4885HDAC2 971/4885
US-20020147333-A1 2-(pyrazol-3-yl)carbapenem derivatives DPEP1, DHPS, JMJD6 HDAC6 1628/4885HDAC1 173/4885HDAC2 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.